Cargando…
Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
Alzheimer’s disease (AD) is the most common form of dementia, with a high impact worldwide, accounting for more than 46 million cases. The continuous increase of AD demands the fast development of preventive and curative therapeutic strategies that are truly effective. The drugs approved for AD trea...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694621/ https://www.ncbi.nlm.nih.gov/pubmed/36365114 http://dx.doi.org/10.3390/pharmaceutics14112296 |
_version_ | 1784837846607069184 |
---|---|
author | Nunes, Débora Loureiro, Joana A. Pereira, Maria Carmo |
author_facet | Nunes, Débora Loureiro, Joana A. Pereira, Maria Carmo |
author_sort | Nunes, Débora |
collection | PubMed |
description | Alzheimer’s disease (AD) is the most common form of dementia, with a high impact worldwide, accounting for more than 46 million cases. The continuous increase of AD demands the fast development of preventive and curative therapeutic strategies that are truly effective. The drugs approved for AD treatment are classified into acetylcholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists. The therapeutic effectiveness of those drugs is hindered by their restricted access to the brain due to the blood–brain barrier, low bioavailability, and poor pharmacokinetic properties. In addition, the drugs are reported to have undesirable side effects. Several drug delivery systems (DDSs) have been widely exploited to address these issues. DDSs serve as drug carriers, combining the ability to deliver drugs locally and in a targeted manner with the ability to release them in a controlled and sustained manner. As a result, the pharmacological therapeutic effectiveness is raised, while the unwanted side effects induced by the unspecific distribution decrease. This article reviews the recently developed DDSs to increase the efficacy of Food and Drug Administration-approved AD drugs. |
format | Online Article Text |
id | pubmed-9694621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96946212022-11-26 Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs Nunes, Débora Loureiro, Joana A. Pereira, Maria Carmo Pharmaceutics Review Alzheimer’s disease (AD) is the most common form of dementia, with a high impact worldwide, accounting for more than 46 million cases. The continuous increase of AD demands the fast development of preventive and curative therapeutic strategies that are truly effective. The drugs approved for AD treatment are classified into acetylcholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists. The therapeutic effectiveness of those drugs is hindered by their restricted access to the brain due to the blood–brain barrier, low bioavailability, and poor pharmacokinetic properties. In addition, the drugs are reported to have undesirable side effects. Several drug delivery systems (DDSs) have been widely exploited to address these issues. DDSs serve as drug carriers, combining the ability to deliver drugs locally and in a targeted manner with the ability to release them in a controlled and sustained manner. As a result, the pharmacological therapeutic effectiveness is raised, while the unwanted side effects induced by the unspecific distribution decrease. This article reviews the recently developed DDSs to increase the efficacy of Food and Drug Administration-approved AD drugs. MDPI 2022-10-26 /pmc/articles/PMC9694621/ /pubmed/36365114 http://dx.doi.org/10.3390/pharmaceutics14112296 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Nunes, Débora Loureiro, Joana A. Pereira, Maria Carmo Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs |
title | Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs |
title_full | Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs |
title_fullStr | Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs |
title_full_unstemmed | Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs |
title_short | Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs |
title_sort | drug delivery systems as a strategy to improve the efficacy of fda-approved alzheimer’s drugs |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694621/ https://www.ncbi.nlm.nih.gov/pubmed/36365114 http://dx.doi.org/10.3390/pharmaceutics14112296 |
work_keys_str_mv | AT nunesdebora drugdeliverysystemsasastrategytoimprovetheefficacyoffdaapprovedalzheimersdrugs AT loureirojoanaa drugdeliverysystemsasastrategytoimprovetheefficacyoffdaapprovedalzheimersdrugs AT pereiramariacarmo drugdeliverysystemsasastrategytoimprovetheefficacyoffdaapprovedalzheimersdrugs |